natgillin/translations-raw huggingface dataset:
The two active ingredients in Irbesartan/Hydrochlorothiazide Teva work together to lower blood pressure further than if either was given alone.
Zdravilni učinkovini v zdravilu Irbesartan/hidroklorotiazid Teva znižujeta krvnitlak, in to še bolj kot če bi jemali vsako učinkovino posebej.
Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled.
Če se intraokularni tlak kljub temu ne zniža, bo morda treba razmisliti o takojšnjem zdravljenju z zdravili ali kirurškem posegu.
Each Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablet contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide.
Vsaka Irbesartan/hidroklorotiazid Teva 150 mg/12,5 mg filmsko obložena tableta vsebuje 150 mg irbesartana in 12,5 mg hidroklorotiazida.
Additional information on individual components: in addition to the adverse reactions listed above for the combination product, other adverse reactions previously reported with one of the individual components may be potential adverse reactions with Irbesartan/Hydrochlorothiazide Teva.
Dodatni podatki o posameznih učinkovinah: poleg zgoraj naštetih neželenih učinkov, ki se lahko pojavijo med uporabo kombiniranega zdravila, se utegnejo med jemanjem zdravila
Adequate monitoring of serum potassium in patients at risk is recommended (see section
Pri bolnikih s povečanim tveganjem je priporočljivo nadzirati vrednosti kalija v serumu (glejte poglavje 4.4).
Interstitial nephritis, renal dysfunction
Bolezni sečil neznana intersticijski nefritis, motnje delovanja ledvic
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets Each film-coated tablet contains 300 mg of irbesartan and 12.5 mg of hydrochlorothiazide.
Irbesartan/hidroklorotiazid Teva 300 mg/12,5 mg filmsko obložene tablete Vsaka filmsko obložena tableta vsebuje 300 mg irbesartana in 12,5 mg hidroklorotiazida.
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide
Irbesartan/hidroklorotiazid Teva 300 mg/12,5 mg filmsko obložene tablete irbesartan/hidroklorotiazid
Each Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablet contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide.
Vsaka Irbesartan/ hidroklorotiazid Teva 300 mg/12.5 mg filmsko obložena tableta vsebuje 300 mg irbesartana in 12,5 mg hidroklorotiazida.
The MAH must ensure that the manufacturing processes of the drug substances used for their drug products are reviewed for the potential risk of formation of Nnitrosamines and changed as necessary to minimise nitrosamine contamination as much as possible.
N-nitrozaminov in jih po potrebi spremeniti tako, da se onesnaženje z nitrozamini čim bolj zmanjša.
Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dosedependent association between HCTZ and NMSC has been observed (see also sections 4.4 and 5.1).
Nemelanomski kožni rak: Na podlagi obstoječih podatkov epidemioloških študij so ugotovili, da obstaja razmerje med kumulativnim odmerkom hidroklorotiazida in nemelanomskim kožnim rakom
No dosage adjustment of Irbesartan/Hydrochlorothiazide Teva is necessary in older people.
Zdravilo Irbesartan/hidroklorotiazid Teva je potrebno zaužiti.
Additional information on hydrochlorothiazide interactions When administered concurrently, the following medicinal products may interact with thiazide diuretics:
Ob sočasni uporabi se lahko pojavijo interakcije med tiazidnimi diuretiki in naslednjimi zdravili: Alkohol
This medicine has been prescribed for you only.
Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
Tablet coating for 150 mg/12.5 mg strength: hypromellose, titanium dioxide, polyethylene glycol 6000 (macrogol), polyethylene glycol 400 (macrogol), iron oxide red, iron oxide yellow and iron oxide black.
Filmska obloga za jakosti 150 mg/12,5 mg in 300 mg/12,5 mg: hipromeloza titanov dioksid polietilenglikol 6000 (makrogol) polietilenglikol 400 (makrogol)
Additional information on irbesartan interactions
Dodatni podatki o medsebojnem delovanju s hidroklorotiazidom
Tablet coating for 300 mg/12.5 mg strength: hypromellose, titanium dioxide, polyethylene glycol 6000 (macrogol), polyethylene glycol 400 (macrogol), iron oxide red, iron oxide yellow and iron oxide black.
Filmska obloga za jakost 300 mg/25 mg: hipromeloza titanov dioksid polietilenglikol 6000 (makrogol) polietilenglikol 400 (makrogol)
Corticosteroids, ACTH Electrolyte depletion, particularly hypokalaemia, may be increased;
Znižanje elektrolitov, še posebej kalija (hipokaliemija).
Posology
Zdravila
Cardiac arrhythmias
hemolitična anemija,
Dosage adjustments of antigout medicinal products may be necessary as hydrochlorothiazide may raise the level of serum uric acid.
Zdravila za zdravljenje protina Hidroklorotiazid lahko zveča serumsko koncentracijo sečne kisline, zato je treba v takem primeru odmerek zdravil za zdravljenje protina prilagoditi.
Jaundice (intrahepatic cholestatic jaundice)
Bolezni jeter, žolčnika in žolčevodov neznana zlatenica (intrahepatska holestatska zlatenica)
Package leaflet: information for the patient Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets irbesartan / hydrochlorothiazide
Navodilo za uporabo Irbesartan/hidroklorotiazid Teva 300 mg/25 mg filmsko obložene tablete irbesartan / hidroklorotiazid
Not known:
niso ugotavljali.
Vertigo, paraesthesia, lightheadedness, restlessness
Bolezni živčevja neznana vrtoglavica, parestezija, omotica, nemir
For N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) the MAH must introduce the following specifications for the drug substance:
Imetnik dovoljenja za promet z zdravilom mora za N-nitrozodimetilamin (NDMA) in
Loop diuretics are preferred to thiazides in this population.
Za te bolnike so bolj kot tiazidi primerni diuretiki Henlejeve zanke.
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets are light pink to pink, film coated capsule shaped tablets.
Izgled zdravila Irbesartan/hidroklorotiazid Teva in vsebina pakiranja Irbesartan/hidroklorotiazid Teva 150 mg/12,5 mg filmsko obložene tablete so svetlo rožnate do rožnate, filmsko obložene tablete v obliki kapsul.
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets are light pink to pink, film coated capsule shaped tablets.
Izgled zdravila Irbesartan/hidroklorotiazid Teva in vsebina pakiranja Irbesartan/hidroklorotiazid Teva 300 mg/12,5 mg filmsko obložene tablete so svetlo rožnate do rožnate, filmsko obložene tablete v obliki kapsul.
These 24-hour effects were observed without excessive blood pressure lowering at peak and are consistent with safe and effective blood-pressure lowering over the once-daily dosing interval.
Pri odmerjanju enkrat na dan je bilo znižanje krvnega tlaka varno in učinkovito.
No dosage adjustment of Irbesartan/Hydrochlorothiazide Teva is necessary in patients with mild to moderate hepatic impairment (see section 4.3).
Pri bolnikih z blago do zmerno jetrno okvaro prilagoditev odmerka ni potrebna (glejte poglavje 4.3).
Once daily dosing with 150 mg irbesartan and 12.5 mg hydrochlorothiazide gave systolic/diastolic mean placebo-adjusted blood pressure reductions at trough (24 hours post-dosing) of 12.9/6.9 mmHg in patients with mild-to-moderate hypertension.
mg hidroklorotizida, se je 24 ur po zaužitju odmerka sistolični krvni tlak znižal za 12,9 mmHg bolj kot po uporabi placeba, diastolični pa za 6,9 mmHg.
Package leaflet: information for the patient Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets irbesartan / hydrochlorothiazide
Navodilo za uporabo Irbesartan/hidroklorotiazid Teva 150 mg/12,5 mg filmsko obložene tablete irbesartan / hidroklorotiazid
Povidone
Odmerjanje
How to store Irbesartan/Hydrochlorothiazide Teva
Kaj vsebuje zdravilo Irbesartan/hidroklorotiazid Teva
Suggested measures include induction of emesis and/or gastric lavage.
Pri bolniku je priporočeno izzvati bruhanje in/ali mu izprati želodec.
Thiazide diuretic-associated azotaemia may occur in patients with impaired renal function.
Pri bolnikih z okvarjeno ledvično funkcijo se lahko zaradi jemanja tiazidnih diuretikov pojavi azotemija.
Pressor amines (e.g. noradrenaline) The effect of pressor amines may be decreased, but not sufficiently to preclude their use;
Učinkovitost presornih aminov se lahko zmanjša, vendar ne za toliko, da bi bilo treba zdravljenje zato ustaviti.
Jaundice Hepatitis, abnormal liver function
Žilne bolezni neznana ortostatska hipotenzija
Musculoskeletal and connective tissue disorders:
Bolezni mišično-skeletnega sistema in vezivnega tkiva neznana oslabelost, mišični krč
Because no information is available regarding the use of Irbesartan/Hydrochlorothiazide Teva during breast-feeding, Irbesartan/Hydrochlorothiazide Teva is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Ker podatkov o uporabi zdravila Irbesartan/hidroklrotiazid Teva med dojenjem ni, se zdravilo
Package leaflet: information for the patient Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets irbesartan / hydrochlorothiazide
Navodilo za uporabo Irbesartan/hidroklorotiazid Teva 300 mg/12,5 mg filmsko obložene tablete irbesartan / hidroklorotiazid
If you experience these, talk to your doctor before attempting to drive or use machines.
V tem primeru se morate o sposobnosti upravljanja vozil in strojev posvetovati s svojim zdravnikom.
- Tilt your head back.
- Nagnite glavo nazaj.
- Put yourself in a comfortable and stable position.
- Postavite se v udoben in stabilen položaj.
After first opening: 4 weeks.
Po prvem odprtju: 4 tedne.
Treatment effect was evaluated up to 29 days.
Učinek zdravljenja so ocenjevali do 29 dni.
Risk Management Plan (RMP)
Načrt za obvladovanje tveganj (RMP)
Use a single dose as soon as you remember.
Vzemite en odmerek, takoj ko se spomnite.
Date of first authorisation: 18.05.2011 Date of latest renewal: 11.01.2016
Datum prve odobritve: 18.05.2011 Datum zadnjega podaljšanja: 11.01.2016
The treatment should not exceed 2 weeks as safety data beyond this is not available.
Zdravljenje ne sme trajati več kot 2 tedna, saj varnostni podatki za daljše obdobje niso na voljo.
In vitro, the 99.8% were bound to proteins in human plasma.
In vitro se 99,8 % odmerka veže na beljakovine v humani plazmi.
It works by blocking certain substances involved in causing inflammation.
Deluje tako, da zavira nekatere snovi, ki so udeležene pri povzročanju vnetja.
Continue with the next regularly scheduled dose.
Nadaljujte z naslednjim rednim odmerkom.
Excipient(s) with known effect:
Pomožna(e) snov(i) z znanim učinkom:
Pack of 1 bottle.
Pakiranje z 1 plastenko.
If you use any other eye drops, wait at least five minutes between using Yellox and the other drops.
Če uporabljate katere koli druge kapljice za oči, počakajte vsaj pet minut med uporabo zdravila Yellox in drugih kapljic.
Do not put in any more drops until it is time for your next regular dose.
Ne jemljite dodatnih kapljic, dokler ni čas za naslednji redni odmerek.
Do not use Yellox longer than 2weeks.
Zdravila Yellox ne uporabljajte dlje kot 2 tedna.
Warning and precautions
Opozorila in previdnostni ukrepi
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obvestite zdravnika ali farmacevta, če uporabljate, ste pred kratkim uporabljali ali pa boste morda začeli uporabljati katero koli drugo zdravilo.
The difference in the rate of inflammation clearance showed as early as day 3.
Razlika v stopnji odpravljanja vnetja se je pokazala že 3. dan študije.
- Wash your hands before using the eye drops.
- Pred uporabo kapljic za oko si umijte roke.
Contact with soft contact lenses must be avoided.
Stiku z mehkimi kontaktnimi lečami se je treba izogibati.
Therefore, treating individuals who have previously exhibited sensitivities to these medicinal products has to be avoided (see section 4.3).
Zato se je uporabi zdravila pri osebah, pri katerih se je v preteklosti pojavila občutljivost za ta zdravila, treba izogibati (glejte poglavje 4.3).
There are no adequate data from the use of bromfenac in pregnant women.
Ni zadostnih podatkov o uporabi bromfenaka pri nosečnicah.
The doctor may prescribe this medicine during pregnancy if expected benefit to mother outweigh possible risk to baby.
Zdravnik vam lahko predpiše to zdravilo med nosečnostjo, če pričakovana korist za mater odtehta možno tveganje za otroka.
In addition the systemic exposure to bromfenac is negligible; for this reason no pregnancy testing or contraceptive measures are required.
Poleg tega je sistemska izpostavljenost bromfenaku zanemarljiva, zato testi nosečnosti ali kontracepcijski ukrepi niso potrebni.
If it is almost time for the next dose, leave out the missed dose.
Če je že skoraj čas za naslednji odmerek, pozabljenega odmerka ne vzemite.
Based on clinical data available, a total of 3.4% of patients experienced one or more adverse reactions.
Glede na razpoložljive klinične podatke se je en ali več neželenih učinkov pojavilo pri skupno 3,4 % bolnikov.
Detailed information on this medicine is available on the website of the European Medicines Agency http://www.ema.europa.eu
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you use Yellox.
Če ste noseči ali dojite, menite, da bi lahko bili noseči, ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden vzamete zdravilo Yellox.
Yellox should not be used during the last three months of pregnancy.
Zdravila Yellox ne smete uporabljati v zadnjih treh mesecih nosečnosti.
Discard any unused contents 4 weeks after first opening.
Neuporabljeno vsebino zavrzite 4 tedne po prvem odprtju.
If more than one topical ophtalmic medicinal product is being used, each one should be administered at least 5 minutes apart.
Če se uporablja več kot eno topično oftalmično zdravilo, je treba posamezna zdravila uporabiti z vsaj 5-minutnimi presledki.
Discard the bottle 4 weeks after first opening to prevent infection even if there is solution remaining.
Plastenko zavrzite 4 tedne po prvem odprtju, da preprečite okužbe, tudi če je v plastenki še tekočina.
No interactions with antibiotic eye drops used in conjunction with surgery have been reported.
O medsebojnem delovanju z antibiotičnimi kapljicami za oko, ki se uporabljajo v povezavi s kirurškimi posegi, niso poročali.
The safety and efficacy of bromfenac in paediatric patients has not been established.
Varnost in učinkovitost bromfenaka pri pediatričnih bolnikih še nista bili dokazani.
Jankovcova 1569/2c 17000 Praha 7
Jankovcova 1569/2c 170 00 Praga 7
Yellox has minor influence on the ability to drive and use machines.
Zdravilo Yellox ima manjši vpliv na sposobnost vožnje in upravljanja s stroji.
The following adverse reactions were classified according to the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
Naslednji neželeni učinki so razvrščeni v skladu z naslednjim dogovorom: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) ali zelo redki (< 1/10.000).
However, because of the known effects of prostaglandin biosynthesis-inhibiting medicinal products on the foetal cardiovascular system (closure of ductus arteriosus), the use of Yellox during third trimester pregnancy should be avoided.
Vendar pa se je zaradi znanih učinkov zdravil, ki zavirajo biosintezo prostaglandinov, na kardiovaskularni sistem ploda (zaprtje ductusa arteriosusa) treba izogibati uporabi zdravila Yellox med tretjim trimesečjem nosečnosti.
No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breastfeeding woman to bromfenac is negligible.
Učinkov na dojene novorojence/otroke se ne pričakuje, ker je sistemska izpostavljenost doječih mater bromfenaku zanemarljiva.
The recommended dose is one drop of Yellox in the affected eye(s) twice daily (morning and evening).
Priporočeni odmerek je ena kapljica zdravila Yellox v prizadeto oko dvakrat na dan (zjutraj in zvečer).
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation Application and any subsequent updates of the RMP.
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
The use of Yellox is in general not recommended during pregnancy unless the benefit outweighs the potential risk.
Uporaba zdravila Yellox med nosečnostjo na splošno ni priporočljiva, razen kadar koristi odtehtajo morebitno tveganje.
Cross-sensitivity
Navzkrižna občutljivost
One drop contains approximately 33 micrograms bromfenac.
Ena kapljica vsebuje približno 33 mikrogramov bromfenaka.
Pregnancy , breastfeeding and fertility
Nosečnost, dojenje in plodnost
Therefore, patients should be advised not to wear contact lenses during treatment with Yellox.
Zato je treba bolnikom svetovati, naj med zdravljenjem z zdravilom Yellox ne uporabljajo kontaktnih leč.
Write the date of opening on the carton label in the space provided.
Zapišite datum odprtja na predviden prostor na škatli.
In these studies, study substance was administered approximately 24 hours after cataract surgery and continued for up to 14 days.
V teh študijah so preiskovano učinkovino uporabili približno 24 ur po kirurški odstranitvi katarakte, uporaba pa se je nadaljevala do 14 dni.
Do not use this medicine after the expiry date which is stated on the bottle and outer carton after “EXP”.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki in škatli poleg oznake »EXP«.
In a large, well-controlled study that was conducted in Japan, Yellox was shown to be as effective as pranoprofen ophthalmic solution.
V veliki, dobro nadzorovani študiji, ki so jo izvedli na Japonskem, so pokazali, da je zdravilo Yellox enako učinkovito kot raztopina za oko s pranoprofenom.
Email: czech.info@valeant.com
E-naslov: czech.info@valeant.com
The European Medicines Agency has waived the obligation to submit the results of studies with Yellox in all subsets of the paediatric population in postoperative ocular inflammation (see section 4.2 for information on paediatric use)
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Yellox za vse podskupine pediatrične populacije pri zdravljenju pooperacijskega vnetja očesa (za informacije o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Following twice daily dosing with bromfenac eye drops plasma concentrations were not quantifiable.
Po odmerjanju kapljic za oči z bromfenakom dvakrat na dan koncentracij v plazmi ni bilo mogoče izmeriti.
Accidental administration of more than one drop should not result in increased topical exposure as excessive volume would rinse out of the eye due to limited conjunctival sac capacity.
Nenamerna uporaba več kot ene kapljice ne bi smela povzročiti povečane lokalne izpostavljenosti, saj se zaradi omejene kapacitete veznične vrečke odvečna količina izpere iz očesa.
Do not stop using Yellox without speaking to your doctor.
Zdravila Yellox ne prenehajte uporabljati, dokler se ne posvetujete z zdravnikom.
- Keep the bottle tightly closed when not in use.
- Plastenka naj bo tesno zaprta, kadar je ne uporabljate.
Patients should be instructed to keep the bottle tightly closed when not in use.
Bolnikom je treba svetovati, naj plastenko tesno zaprejo, kadar je ne uporabljajo.
- if you have experienced asthma, skin allergy or intense inflammation in your nose when using other NSAIDs.
- če imate astmo, kožno alergijo ali močno vnetje nosu, kadar uporabljate druga nesteroidna protivnetna zdravila.
The table below describes adverse reactions by system organ class and frequency.
V spodnji preglednici so neželeni učinki razvrščeni po organskem sistemu in pogostnosti.
Bromfenac efficiently permeates the cornea of cataract patients: A single dose resulted in a mean peak aqueous humour concentrations of 79±68 ng/ml at 150-180 minutes after dosing.
Bromfenak učinkovito prehaja skozi roženico bolnikov s katarakto: enkratni odmerek je povzročil povprečno največjo koncentracijo v prekatni vodki 79 ± 68 ng/ml 150-180 minut po odmerjanju.
Two Phase II multicentre, randomised, double-masked, parallel group studies were conducted in Japan, and two Phase III multicentre, randomised (2:1), double-masked, parallel group, placebocontrolled studies were conducted in the US to assess the clinical safety and efficacy of Yellox dosed twice daily in the treatment of post-operative inflammation in patients undergoing cataract surgery.
Na Japonskem so izvedli dve multicentrični, randomizirani, dvojno slepi študiji 2. faze z vzporednimi skupinami in v ZDA dve multicentrični, randomizirani (2 : 1), dvojno slepi, s placebom nadzorovani študiji 3. faze z vzporednimi skupinami, v katerih so ocenili klinično varnost in učinkovitost zdravila Yellox v odmerku dvakrat na dan pri zdravljenju pooperacijskega vnetja pri bolnikih, pri katerih so opravili kirurško odstranitev katarakte.
Bromfenac is a non-steroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity which is thought to be due to its ability to block prostaglandin synthesis by inhibiting primarily cyclooxygenase 2 (COX-2).
Bromfenak je nesteroidno protivnetno zdravilo (NSAID) s protivnetnim delovanjem, za katerega domnevajo, da je posledica zmožnosti preprečevanja sinteze prostaglandinov prek zaviranja predvsem ciklooksigenaze 2 (COX-2).
Do not use Yellox while wearing contact lenses, since benzalkonium chloride is known to discolour them.
Zdravila Yellox ne uporabljajte, kadar nosite kontaktne leče, saj je znano, da jih benzalkonijev klorid lahko obarva.
- The active substance is bromfenac.
- Zdravilna učinkovina je bromfenak.
It is unknown whether bromfenac or its metabolites are excreted in human milk.
Ni znano, ali se bromfenak ali njegovi presnovki izločajo v materino mleko pri človeku.
After oral administration of 14C-bromfenac to healthy volunteers, urinary excretion was found to be the major route of radioactive excretions, accounting for approximately 82% while faecal excretion represented approximately 13% of the dose.
Po peroralni uporabi 14C-bromfenaka pri zdravih prostovoljcih so ugotovili, da je izločanje z urinom glavna pot izločanja označenega izotopa in da znaša približno 82 %, medtem ko se z blatom izloči približno 13 % odmerka.
Yellox contains bromfenac and belongs to a group of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Zdravilo Yellox vsebuje bromfenak in spada v skupino zdravil, imenovanih nesteroidna protivnetna zdravila (NSAID).
Pharmacotherapeutic group: Ophtalmologicals, Antiinflammatory agents, non-steroids, ATC code: S01BC11.
Farmakoterapevtska skupina: Zdravila za očesne bolezni, protivnetna zdravila, nesteroidna protivnetna zdravila, oznaka ATC: S01BC11
Other medicines and Yellox
Druga zdravila in zdravilo Yellox
Yellox can be used during breast-feeding.
Zdravilo Yellox se lahko uporablja med dojenjem.
Hypersensitivity to bromfenac or to any of the excipients listed in section 6.1, or to other nonsteroidal anti-inflammatory medicinal products (NSAIDs).
Preobčutljivost na bromfenak ali katero koli pomožno snov, navedeno v poglavju 6.1, ali na druga nesteroidna protivnetna zdravila (NSAID).
If blurred vision occurs at instillation patients should be advised to refrain from driving or using machines until vision is clear.
Če se po vkapanju pojavi zameglitev vida, je treba bolniku svetovati, naj se izogiba vožnji ali uporabi strojev, dokler se vid ne zbistri.
Ask your pharmacist how to throw away of medicines you no longer use.
O načinu odstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte s farmacevtom.